https://www.selleckchem.com/pr....oducts/incb059872-di
anxiety assessments were observed for ACT-539313. Besides reports of stress related to the challenge, the most frequently reported adverse events were somnolence and headache. No clinically relevant effects in other safety assessments were observed. Multiple-dose administration of ACT-539313 was safe and well tolerated up to multiple doses of 200mg b.i.d. The drug's PK properties as well as the pattern of a decrease in stress-related symptoms after the CO challenge support further investigations of ACT-539313. Multipl
Like
Comment
Share
